WAITING FOR PFE EPIC COMEBACKThe US-listed pharmaceuticals outperformed the US bourse on the first trading day of 2024. Standing in contrast..
PFE trade ideas
Health Canada Approval of ABRYSV Paves the Way for Pfizer
In a significant stride towards enhancing public health, Health Canada has recently granted approval for Pfizer's groundbreaking bivalent Respiratory Syncytial Virus (RSV) vaccine, ABRYSVO™. This development is a crucial step in safeguarding both older adults and infants through maternal immunization. With the potential to revolutionize preventive healthcare, ABRYSVO™ addresses the prevention of lower respiratory tract diseases caused by RSV, catering to individuals aged 60 and above and infants from birth through 6 months.
Protecting the Vulnerable Populations:
The approval of ABRYSVO™ presents a new and vital option for protecting individuals most susceptible to severe RSV infections. Infants, particularly those under one year, face an increased risk of hospitalization due to RSV infection. Older adults also bear a significant burden of costs associated with the disease. Pfizer's vaccine aims to provide a comprehensive solution, mitigating the impact of RSV across different age groups and reducing the strain on healthcare resources.
Maternal Immunization as a Strategic Approach:
Dr. Darine El-Chaâr, a Maternal Fetal Medicine physician at The Ottawa Hospital, emphasizes the critical role of maternal immunization in bridging the vulnerability gap during the first few months of an infant's life. By administering vaccines to pregnant individuals, the approach not only protects the newborns but also safeguards mothers who may face an increased risk of severe disease compared to non-pregnant women. This strategic approach aligns with Pfizer's commitment to making a positive contribution to public health and community well-being.
Pfizer's Commitment to Public Health:
Andréa Mueller, Primary Care Portfolio Lead at Pfizer Canada, expresses pride in Pfizer's decades-long experience in vaccine development. The company's commitment to public health is evident in its dedication to providing effective solutions for preventing illness and reducing the strain on healthcare systems. The approval of ABRYSVO™ represents Pfizer's ongoing commitment to advancing healthcare solutions and making a positive impact on global well-being.
Market Analysis:
While the approval of ABRYSVO™ marks a significant milestone for Pfizer's contribution to public health, the technical analysis of Pfizer's stock indicates a falling trend channel in the medium to long term. Investors appear to have sold at lower prices over time, reflecting negative sentiments towards the company. However, it's essential to note that market trends are dynamic, and the approval of a groundbreaking vaccine may influence investor perceptions in the future.
Conclusion:
Pfizer's Health Canada approval for ABRYSVO™ brings hope for enhanced protection against RSV infections, benefiting both older adults and infants. The strategic focus on maternal immunization highlights Pfizer's commitment to addressing healthcare challenges comprehensively. As the company works towards making ABRYSVO™ available to Canadians, the market will likely closely watch how this groundbreaking vaccine contributes not only to public health but also to Pfizer's future trajectory in the pharmaceutical landscape.
PFE UpdatePFE have risen from crucial 0.786 fibo and currently WYCKOFF Accumulation is formed and stable.
SL is $27-$28 and year end target is shown.
Bullish structure.
Pfizer looking attractivePfizer is experiencing the most aggressive sell-off in its history and technicals are aligning for a possible reversal. The stock has given back all of its COVID-19-induced gains and probably giving us a first entry opportunity.
Extremely Bullish on PFE. Nice swing trade opportunity.Here in this video, I break down very specifically why I think that NYSE:PFE is going up. Please pay attention and retain the information! Thank you as always for watching my analysis and I pray you have a beautiful new years!
Colossians 3:23-24
PFENot a recommendation, educational purpose only. This is one of the stocks that has been falling constantly throughout the year and now appears to be bouncing back. I bought some in 28s and sold covered call at 29 recently, not so lucky as the stock is nearing $30. It is possible, this can retest $25 -$26, the stock has potential to hit T1= $31.5, T2 = $34 provided bounce back is intact.
PFE opportunity or value trap?I have been following PFE for a while last year and almost added it as a staple to my core dividend portfolio which is about 25% of my long-term investing portfolio. The stock just printed its first whole bodied green candle since December of two years ago. The RSI is at historical levels not seen since 2009. The PE ratio has expanded a bit but still offers some multiple expansion here.
With a dividend over 5% and the stock having a huge margin of safety, this could be a strong bet to outperform money markets and provide a decent return. The stock rides the lower end of the Bollinger bands, it also saw 9 straight down months last year, similar to Verizon. I am very close to adding a huge chunk here before 30$. Even a 10% return this year with that 5% dividend is a win in these unsure markets.
$PFE at key level of supportBuying some NYSE:PFE shares at current level of support, SL at roughly $26 aiming for a risk-reward of 1:3.
Reason to enter this trade - price is at key support level, with bullish ice cream bar formed at weekly levels (week of 18th Dec 2023).
First trade of 2024, let's start the year with a bang!
PFE Pfizer Inc STRONG BUYPFE Pfizer, a darling of the Covid pandemic era is currently down from 56$
Pfizer emerged as a significant beneficiary during the Covid-19 era, witnessing a surge in its stock price. However, as the Covid-19 concern recedes, its share price has also returned most of its gains. Nevertheless, Pfizer's success isn't solely dependent on a single event, as it possesses a diverse portfolio of drugs that contribute to a more varied revenue stream. Although the Covid-19 vaccines brought substantial profits to Pfizer, its resilience lies in its broader pharmaceutical offerings. Morningstar has provided a fair valuation of $48, indicating a potential upside of 46%.
Conservatives target are at $36 - $42 still a massive upside opportunity
PFEPFE hit a high of $62 and has since dropped more then 50% of the value. Looking at the waves, if fibo 0.786 holds then it would likely be a V recovery.
Watch this space.
miss 100% of shots you don't take. very interesting setup here with volume coming and a bottom hit exactly 52 weeks from top.
PFEPFE is still on a downtrend projectory based on 10wk chart. Strong resistance at big red box.
Test trendline at $20 then will see.
As much as I hate the company, looks like a good time.RSI is extremely low. Fear and uncertainty everywhere. Trade stocks others don't like. Not stocks everyone loves. I'll remind you guys in 6 months when it's 40$+🤝
PFE : A high-risk high-reward opportunityThe exponential growth of Pfizer during the COVID era can be attributed significantly to its role as a vaccine producer. However, the current levels of PFE are even lower than the pre-COVID trading price. The current stock price is approaching the lowest levels witnessed during the COVID-induced market crash. Consequently, almost all the increase in price driven by the COVID vaccine narrative is not reflected in the current stock price.
I perceive potential in Pfizer as a robust company at its current valuation.
I have entered the market twice at various levels, resulting in a total position size of approximately 1.85% of my capital. I am contemplating additional purchases to augment the position size to 2.5% of the capital. Will update underneath this post if and when I do so.
At present, my intention is to retain the position until the stock reaches its all-time high, presenting a potential upside move of about 122%.
Time to buy? First target 35?Its way overbought and numbers looks good. Technically sitting at a good support and can jump anytime. Within 3-5 years, it can give you back 70% gains.
$PFENot often you see a weekly chart this clean. This has been the line in the sand for 25yrs. Chart is self explanatory. If you have time and are patient this could be a good R/R
Pfizer.... Start buildingPfizer is one of those companies that we all feel has been shady and the stock value shows it. As much as human emotion can draw this value down, hedge funds and smart money will start stepping in now. The chart says it all. We are talking about one of the longest running publically traded companies folks, this will rebound. Its not a matter of if, but when.
I have started a minor position in Pfizer today and plan to DCA weekly small amount until we form a bullish trend.
Good luck!
Pfizer (NYSE: $PFE) Stock SinksKey Takeaway
1. Shares of Pfizer tanked Wednesday as investors digested the subpar guidance, falling as much as 9% to below $26 in morning trading, hitting their lowest intraday share price since 2013. That’s the largest single-day drop for Pfizer since January 2009.
2. Pfizer said Wednesday it expects 2024 revenue to come in between $58.5 billion and $61.5 billion, representing roughly zero growth from 2023’s forecasts and coming in well below analysts’ average 2024 projected sales of $62.6 billion, according to FactSet.
3. Notably, Pfizer said it expects 2024 sales for its Covid products—Paxlovid pills and the Comirnaty vaccine—to be about $8 billion, a nearly 90% drop from the roughly $57 billion of revenue its Covid series brought in last year.
PFE updateThis scenario is what i am looking for, reclaim yellow line above and most likely this set-up gets invalidated. Until then, patience is needed.
PFERisk and reward...
Oversold here severely at 26$ support.
This is a long term investment idea ..
I think Pfe will retrace back to mid 30's by next year..
Pfe is back to feb 2020 covid crash levels. 26$ support has held for over a decade.
Pfizer P/E tied to decline; strong dividend option?Pfizer has an extensive history of high dividend yield: 5.73% TTM, up significantly since the sharp 2020-2021 decline--payout ratio 90.08%. However, a significant decline in earnings is tied directly to a share price decline. Unsure if recovery is expected, good horizons: approval in EU (small) } Bad horizons: Pfizer's uncontested market share/exclusivity decline, lack of meaningful pipeline, . Can we expect a dividend increase?
